Ideal use case: Lenti.RiGHT® is ideally suited for later-phase clinical trials and commercial production.
Consistency and reproducibility: With all lentiviral packaging genes and the transfer vector stably integrated, these production cells ensure consistent vector production, which is critical for clinical applications where batch-to-batch variability must be minimized.
High yield and efficiency: These cells are engineered for optimal expression of all necessary components, leading to high-yield production suitable for the large-scale manufacturing that will be required in later-phase clinical trials and commercial production.
Simplified manufacturing: The stable integration of all components streamlines the manufacturing process, thereby reducing the complexity and variability associated with transient transfections and ensuring a more robust production pipeline. Initial and early material can be provided from clone pool production.
Cost-effectiveness: Over time, the use of these stable production cell lines can be more cost-effective due to reduced variability, elimination of the need for repeated transfections, and consistent high yields, leading to lower overall production costs.
